Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
BRCA mutation
i
Other names:
BRCA, Breast cancer, early onset
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related biomarkers:
Expression
CNA
Others
‹
BRCA deletion (1)
BRCA deletion (1)
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
BRCA mutation
HER2 Negative Breast Cancer
BRCA mutation
HER2 Negative Breast Cancer
rivoceranib + fluzoparib
Sensitive: B - Late Trials
rivoceranib + fluzoparib
Sensitive
:
B
rivoceranib + fluzoparib
Sensitive: B - Late Trials
rivoceranib + fluzoparib
Sensitive
:
B
BRCA mutation
Pancreatic Ductal Adenocarcinoma
BRCA mutation
Pancreatic Ductal Adenocarcinoma
PARP inhibitor
Sensitive: D – Preclinical
PARP inhibitor
Sensitive
:
D
PARP inhibitor
Sensitive: D – Preclinical
PARP inhibitor
Sensitive
:
D
BRCA mutation
Diffuse Large B Cell Lymphoma
BRCA mutation
Diffuse Large B Cell Lymphoma
loncastuximab tesirine-lpyl
Sensitive: D – Preclinical
loncastuximab tesirine-lpyl
Sensitive
:
D
loncastuximab tesirine-lpyl
Sensitive: D – Preclinical
loncastuximab tesirine-lpyl
Sensitive
:
D
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.